Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment
Marginal zone lymphomas (MZLs) represent a clinical challenge in that the heterogeneity and relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. In recent years, improved understanding of the complex pathobiology of MZLs has resulted in the development of novel treatment strategies. Accurate diagnosis of the subtype of MZL is essential to select the appropriate management strategy for the individual patient. Clinicians need to understand the importance of treating the underlying infectious condition in patients with MZLs. Educating clinicians about the biology of MZLs, novel therapeutic approaches and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
This information was originally presented at the NCCN 2020 Virtual Congress: Hematologic Malignancies™ held on October 9-10, 2020.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.
Following this program, participants should be able to:
- Describe the etiology and genetic features implicated in the pathogenesis of different subtypes of marginal zone lymphoma (MZL).
- Review the current treatment approaches for patients with MZL based on the individual subtype.
- Discuss the data from clinical trials on the use of targeted therapies for the treatment of patients with MZL.
Stephen D. Smith, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Stephen D. Smith, MD
Acerta Pharma: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
*Ayala: Consulting Fee; Grant/Research Support
Bayer HealthCare: Grant/Research Support
BeiGene: Grant/Research Support; Scientific Advisor
*Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support
Denovo Biopharma: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support
*Ignyta: Grant/Research Support
*Incyte Corporation: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee
Kite Pharma: Consulting Fee
Merck & Co., Inc.: Grant/Research Support
Millennium Pharmaceuticals, Inc.: Consulting Fee
Portola Pharmaceuticals, Inc.: Grant/Research Support
* signifies the relationship relates to the individual's spouse/partner
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Michael Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Leadership listed below discloses the following relevant financial relationships:
Wui-Jin Koh, MD: IBM Watson Health for Oncology and Genomics; Scientific Advisor
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Mary A. Dwyer, MS, CGC; Hema Sundar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.50 contact hour.
NCCN designates this knowledge-based continuing education activity for 0.50 contact hour (0.05 CEUs) of continuing education credit. UAN: JA4008196-0000-20-127-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until October 30, 2021. PAs should only claim credit commensurate with the extent of their participation.
- 0.50 AAPA Category 1 CME credit
- 0.50 ACPE contact hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC contact hours
- 0.50 Participation
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing